Statins are potential anticancerous agents (Review)

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1019-1039

  Altwairgi, Abdullah K ^a  

^a KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

Cancer; Clinical studies; Populationbased studies; Preclinical studies; Statins

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; FLUINDOSTATIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; RIBONUCLEOPROTEIN; RIBONUCLEOPROTEIN A1; SIMVASTATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL CYCLE G1 PHASE; COHORT ANALYSIS; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ESOPHAGUS CANCER; HEREDITY; HUMAN; IN VITRO STUDY; OBSERVATIONAL STUDY; PLEIOTROPY; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PRENYLATION; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS;

EID: 84921669806     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3741     Document Type: Article

References (133)

1. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 (Internet). Lyon, France: International Agency for Research on Cancer. 2013. Available from: http://globocan. iarc.fr. Accessed.
2. Kanu OO, Mehta A, Di C, Lin N, et al: Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 13:701-718, 2009.
3. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990.
4. Gazzerro P, Proto MC, Gangemi G, et al: Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 64:102-146, 2012.
5. Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res 9:10-19, 2003.
6. Baserga R: Molecular biology of the cell cycle. Int J Radiat Biol Relat Stud Phys Chem Med 49:219-226, 1986.
7. Tapia-Pérez JH, Kirches E, Mawrin C, Firsching R and Schneider T: Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemother Pharmacol 67:1193-1201, 2011.
8. Rao S, Lowe M, Herliczek TW and Keyomarsi K: Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17:2393-2402, 1998.
9. Collisson EA, Kleer C, Wu M, et al: Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2:941-948, 2003.
10. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG and Holt PR: Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5:2223-2229, 1999.
11. Marcelli M, Cunningham GR, Haidacher SJ, et al: Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 58:76-83, 1998.
12. Koyuturk M, Ersoz M and Altiok N: Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 250:220-228, 2007.
13. Baetta R, Donetti E, Comparato C, et al: Pro-apoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res 36:115-121, 1997.
14. Wang IK, Lin-Shiau SY and Lin JK: Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol 86:83-91, 2000.
15. He Z, Mangala LS, Theriot CA, Rohde LH, Wu H and Zhang Y: Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells. J Radiat Res 53:225-233, 2012.
16. Denoyelle C, Vasse M, Korner M, et al: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22:1139-1148, 2001.
17. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K and Tonn JC: Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 20:2761-2771, 2000.
18. Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C and Emmerich B: First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 79:240-243, 2007.
19. Sondergaard TE, Pedersen PT, Andersen TL, et al: A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol 27:17-22, 2009.
20. Bjarnadottir O, Romero Q, Bendahl PO, et al: Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138:499-508, 2013.
21. Garwood ER, Kumar AS, Baehner FL, et al: Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 119:137-144, 2010.
22. Inano H, Suzuki K, Onoda M and Wakabayashi K: Anticarcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. Carcinogenesis 18:1723-1727, 1997.
23. Narisawa T, Fukaura Y, Tanida N, Hasebe M, Ito M and Aizawa R: Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1, 2-dimethylhydrazineinduced colon carcinogenesis in ICR mice. Tohoku J Exp Med 180:131-138, 1996.
24. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M and Aizawa R: Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87:798-804, 1996.
25. Clutterbuck RD, Millar BC, Powles RL, et al: Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol 102:522-527, 1998.
26. Kikuchi T, Nagata Y and Abe T: In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J Neurooncol 34:233-239, 1997.
27. Hawk MA, Cesen KT, Siglin JC, Stoner GD and Ruch RJ: Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett 109:217-222, 1996.
28. Matar P, Rozados VR, Binda MM, Roggero EA, Bonfil RD and Scharovsky OG: Inhibitory effect of lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 17:19-25, 1999.
29. Matar P, Rozados VR, Roggero EA and Scharovsky OG: Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother Radiopharm 13:387-393, 1998.
30. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS and Gomez DE: Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50:83-93, 1998.
31. Broitman SA, Wilkinson JT IV, Cerda S and Branch SK: Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic-metastases-in vivo. Adv Exp Med Biol 401:111-130, 1996.
32. Jani JP, Specht S, Stemmler N, et al: Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13:314-324, 1993.
33. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, et al: Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 6:2044-2052, 2000.
34. Feleszko W, Bałkowiec EZ, Sieberth E, et al: Lovastatin and tumor necrosis factor-α exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81:560-567, 1999.
35. Mucci LA and Stampfer MJ: Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer. J Clin Oncol 32:1-2, 2014.
36. Platz EA, Leitzmann MF, Visvanathan K, et al: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98:1819-1825, 2006.
37. Jespersen CG, Norgaard M, Friis S, Skriver C and Borre M: Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997-2010. Cancer Epidemiol 38:42-47, 2014.
38. Yu O, Eberg M, Benayoun S, et al: Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32:5-11, 2014.
39. Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z and Stanford JL: Statin use in relation to prostate cancer outcomes in a populationbased patient cohort study. Prostate 73:1214-1222, 2013.
40. Ferris JS, McCoy L, Neugut AI, Wrensch M and Lai R: HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer 131:E1031-E1037, 2012.
41. Gaist D, Andersen L, Hallas J, Sorensen HT, Schroder HD and Friis S: Use of statins and risk of glioma: a nationwide casecontrol study in Denmark. Br J Cancer 108:715-720, 2013.
42. Tsibouris P, Vlachou E and Isaacs PE: Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus. World J Gastrointest Pharmacol Ther 5:27-39, 2014.
43. Singh S, Singh AG, Singh PP, Murad MH and Iyer PG: Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 11:620-629, 2013.
44. Beales IL, Hensley A and Loke Y: Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther 4:69-79, 2013.
45. Wu XD, Zeng K, Xue FQ, Chen JH and Chen YQ: Statins are associated with reduced risk of gastric cancer: a meta-analysis. Eur J Clin Pharmacol 69:1855-1860, 2013.
46. Lytras T, Nikolopoulos G and Bonovas S: Statins and the risk of colorectal cancer: an updated systematic review and metaanalysis of 40 studies. World J Gastroenterol 20:1858-1870, 2014.
47. Brewer TM, Masuda H, Liu DD, et al: Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 109:318-324, 2013.
48. McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL and Li CI: Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age. Cancer Epidemiol Biomarkers Prev 22:1529-1537, 2013.
49. Undela K, Srikanth V and Bansal D: Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 135:261-269, 2012.
50. Lavie O, Pinchev M, Rennert HS, Segev Y and Rennert G: The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol 130:615-619, 2013.
51. Liu W, Choueiri TK and Cho E: Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. Cancer 118:797-803, 2012.
52. Singh S, Singh PP, Singh AG, Murad MH and Sanchez W: Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144:323-332, 2013.
53. Pradelli D, Soranna D, Scotti L, et al: Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev 22:229-234, 2013.
54. Bonovas S, Filioussi K and Sitaras NM: Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 103:2646-2651, 2008.
55. Cui X, Xie Y, Chen M, et al: Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 23:1099-1111, 2012.
56. Deng Z, Zhang S, Yi L and Chen S: Can statins reduce risk of lung cancer, especially among elderly people? A meta-analysis. Chin J Cancer Res 25:679-688, 2013.
57. Tan M, Song X, Zhang G, et al: Statins and the risk of lung cancer: a meta-analysis. PLoS One 8:e57349, 2013.
58. Li X, Wu XB and Chen Q: Statin use is not associated with reduced risk of skin cancer: a meta-analysis. Br J Cancer 110:802-807, 2014.
59. da Silva RD, Xylinas E, Kluth L, et al: Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol 190:487-492, 2013.
60. Zhang XL, Geng J, Zhang XP, et al: Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control 24:769-776, 2013.
61. Chan TF, Wu CH, Lin CL and Yang CY: Statin use and the risk of breast cancer: a population-based case-control study. Expert Opin Drug Saf 13:287-293, 2014.
62. Chan TF, Chiu HF, Wu CH, Lin CL and Yang CY: Statin use and the risk of esophageal cancer: a population-based case-control study. Expert Opin Drug Saf 12:293-298, 2013.
63. Kuo CC, Chiu HF, Lee IM, Kuo HW, Lee CT and Yang CY: Statin use and the risk of bladder cancer: a population-based case-control study. Expert Opin Drug Saf 11:733-738, 2012.
64. Chiu HF, Kuo CC, Kuo HW, Lee IM, Lee CT and Yang CY: Statin use and the risk of kidney cancer: a population-based case-control study. Expert Opin Drug Saf 11:543-549, 2012.
65. Cheng MH, Chiu HF, Ho SC and Yang CY: Statin use and the risk of female lung cancer: a population-based case-control study. Lung Cancer 75:275-279, 2012.
66. Nielsen SF, Nordestgaard BG and Bojesen SE: Statin use and reduced cancer-related mortality. N Engl J Med 367:1792-1802, 2012.
67. Cholesterol Treatment Trialists' (CTT) Collaboration; Emberson JR, Kearney PM, Blackwell L, et al: Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy. PLoS One 7:e29849, 2012.
68. Larner J, Jane J, Laws E, Packer R, Myers C and Shaffrey M: A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 21:579-583, 1998.
69. Thibault A, Samid D, Tompkins AC, et al: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491, 1996.
70. Hus M, Grzasko N, Szostek M, et al: Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Ann Hematol 90:1161-1166, 2011.
71. Lee J, Jung KH, Park YS, et al: Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol 64:657-663, 2009.
72. Han JY, Lee SH, Yoo NJ, et al: A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 17:1553-1560, 2011.
73. Hong JY, Nam EM, Lee J, et al: Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemother Pharmacol 73:125-130, 2014.
74. Limburg PJ, Mahoney MR, Ziegler KL, et al; Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res 4:259-269, 2011.
75. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM and Tu SM: Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 9:81-88, 2011.
76. Lopez-Aguilar E, Sepulveda-Vildosola AC, Betanzos-Cabrera Y, et al: Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children. Arch Med Res 39:655-662, 2008.
77. Kornblau SM, Banker DE, Stirewalt D, et al: Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 109:2999-3006, 2007.
78. Graf H, Jungst C, Straub G, et al: Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 78:34-38, 2008.
79. Konings IR, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA and Sleijfer S: The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer 46:3200-3204, 2010.
80. McKenna WG, Weiss MC, Bakanauskas VJ, et al: The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18:849-859, 1990.
81. Miller AC, Kariko K, Myers CE, Clark EP and Samid D: Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 53:302-307, 1993.
82. Rozados VR, Hinrichsen LI, McDonnell J and Scharovsky OG: Lovastatin enhances in vitro radiation-induced apoptosis of rat B-cell lymphoma cells. J Exp Clin Cancer Res 24:55-61, 2005.
83. Butt S, Butt T, Jirstrom K, et al: The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy. Ann Surg Oncol 21:2911-2919, 2014.
84. Mace AG, Gantt GA, Skacel M, Pai R, Hammel JP and Kalady MF: Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum 56:1217-1227, 2013.
85. Werner M, Sacher J and Hohenegger M: Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol 143:715-724, 2004.
86. Holstein SA and Hohl RJ: Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res 25:651-660, 2001.
87. Lishner M, Bar-Sef A, Elis A and Fabian I: Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 49:319-324, 2001.
88. Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P and Fumagalli R: Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N, N'-bis (2-chloroethyl)-Nnitrosourea and β-interferon on human glioma cells. Cancer Res 52:4348-4355, 1992.
89. Wang W, Collie-Duguid E and Cassidy J: Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett 531:415-420, 2002.
90. Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB and Guillem JG: Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 62:1363-1370, 2005.
91. Brennan DJ, Brandstedt J, Rexhepaj E, et al: Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer 10:125, 2010.
92. Lipkin SM, Chao EC, Moreno V, et al: Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res 3:597-603, 2010.
93. Yu CY, Theusch E, Lo K, et al: HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism. Hum Mol Genet 23:319-332, 2014.
94. Sławińska-Brych A, Zdzisińska B and Kandefer-Szersze. M: Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line. Pharmacol Rep 66:121-129, 2014.
95. Yongjun Y, Shuyun H, Lei C, Xiangrong C, Zhilin Y and Yiquan K: Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression. J Neuroimmunol 260:1-8, 2013.
96. Crosbie J, Magnussen M, Dornbier R, Iannone A and Steele TA: Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell line. Biomark Res 1:33, 2013.
97. Al-Haidari AA, Syk I and Thorlacius H: HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation. Biochem Biophys Res Commun 446:68-72, 2014.
98. Ishikawa S, Hayashi H, Kinoshita K, et al: Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Int J Cancer 135:2528-2536, 2014.
99. Chang HL, Chen CY, Hsu YF, et al: Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPKp53-survivin signaling cascade. Biochim Biophys Acta 1830:4053-4064, 2013.
100. Rentala S, Chintala R, Guda M, Chintala M, Komarraju AL and Mangamoori LN: Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells. Biochem Biophys Res Commun 441:586-592, 2013.
101. Peng X, Li W, Yuan L, Mehta RG, Kopelovich L and McCormick DL: Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. PLoS One 8:e70442, 2013.
102. Al-Husein B, Goc A and Somanath PR: Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis. J Cell Physiol 228:2139-2148, 2013.
103. Fang Z, Tang Y, Fang J, et al: Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One 8:e62823, 2013.
104. Islam M, Sharma S, Kumar B and Teknos TN: Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol 49:778-786, 2013.
105. Yu X, Pan Y, Ma H and Li W: Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells. Oncol Res 20:351-357, 2013.
106. Pelaia G, Gallelli L, Renda T, et al: Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells. Cell Prolif 45:557-565, 2012.
107. Chen J, Liu B, Yuan J, et al: Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production. Mol Oncol 6:62-72, 2012.
108. Guterres FA, Martinez GR, Rocha ME and Winnischofer SM: Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway. Exp Cell Res 319:2977-2988, 2013.
109. Pich C, Teiti I, Rochaix P, et al: Statins reduce melanoma development and metastasis through MICA overexpression. Front Immunol 4:62, 2013.
110. Gopalan A, Yu W, Sanders BG and Kline K: Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Cancer Lett 329:9-16, 2013.
111. Park YH, Jung HH, Ahn JS and Im YH: Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochem Biophys Res Commun 439:275-279, 2013.
112. Zhao Z, Cao X, Pan Y, Sha S, Zhao T and Zhang T: Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells. Oncol Res 20:187-195, 2012.
113. Qi XF, Zheng L, Lee KJ, et al: HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis 4:e518, 2013.
114. Zeng M, Gu WY, Jiang TX, et al: Effects of simvastatin on PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1. Zhongguo Shi Yan Xue Ye Xue Za Zhi 20:268-272, 2012 (In Chinese).
115. Yang SS, Li R, Qu X, Fang W and Quan Z: Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells. Cell Immunol 279:96-102, 2012.
116. Shi J, Zhu J, Zhao H, Zhong C, Xu Z and Yao F: Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma. Tumour Biol 34:429-435, 2013.
117. Ma L, Niknejad N, Gorn-Hondermann I, Dayekh K and Dimitroulakos J: Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells. PLoS One 7:e46055, 2012.
118. Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB and Guan YY: Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J Pharmacol 670:356-364, 2011.
119. Araki M, Maeda M and Motojima K: Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate. Eur J Pharmacol 674:95-103, 2012.
120. Liu H, Wang Z, Li Y, Li W and Chen Y: Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo. Neoplasma 60:240-246, 2013.
121. Liao J, Chung YT, Yang AL, et al: Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSLTrp53R172H-Pdx1-Cre mice. Mol Carcinog 52:739-750, 2013.
122. Vitols S, Angelin B and Juliusson G: Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans - in vitro and in vivo studies. Lipids 32:255-262, 1997.
123. Higgins MJ, Prowell TM, Blackford AL, et al: A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat 131:915-924, 2012.
124. Bansal D, Undela K, D'Cruz S and Schifano F: Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One 7:e46691, 2012.
125. Park HS, Schoenfeld JD, Mailhot RB, et al: Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol 24:1427-1434, 2013.
126. Singh PP and Singh S: Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 24:1721-1730, 2013.
127. van der Spek E, Bloem AC, Sinnige HA and Lokhorst HM: High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica 92:e130-e131, 2007.
128. Han JY, Lim KY, Yu SY, Yun T, Kim HT and Lee JS: A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer 117:2178-2185, 2011.
129. Kim WS, Kim MM, Choi HJ et al: Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19:81-83, 2001.
130. Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, et al: Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo. BMC Cancer 12:575, 2012.
131. Kawata S, Yamasaki E, Nagase T, et al: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84:886-891, 2001.
132. Lersch C, Schmelz R, Erdmann J, et al: Treatment of HCC with pravastatin, octreotide, or gemcitabine - a critical evaluation. Hepatogastroenterology 51:1099-1103, 2004.
133. Knox JJ, Siu LL, Chen E, et al: A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 41:523-530, 2005.